Amylin/Calcitonin Receptor Agonism (cagrilintide) Delays gastric emptying, reduces postprandial glucagon, and strongly promotes satiety Modulates appetite-regulating centers in the hindbrain, hypothalamus, and brain reward circuits, directly influencing food intake and choice May transiently activate the renin-angiotensin-aldosterone system with dose escalation, but without blood pressure or electrolyte derangements GLP-1 Receptor Agonism (semaglutide) Stimulates glucose-dependent insulin secretion and suppresses glucagon release to improve glycemic control Reduces appetite and ad libitum energy intake, with central effects on GLP-1R-expressing nuclei in hypothalamus and brainstem Delays gastric emptying and increases satiety, contributing to progressive bodyweight loss Pharmacokinetic Profile Route of Administration Subcutaneous Dosing Frequency Once weekly Route of Administration : Subcutaneous Injection Dosing Frequency: Once weekly Half -life: Cagrilintide: 7-8 days

Histamine is an immune signalling protein that causes allergies and swelling
FDA-approved Oral Semaglutide as the First GLP-1 Pill for Weight Loss The first FDA-approved oral semaglutide is a revolutionary GLP-1 pill that delivers powerful weight loss results without the need for needles
While AHK-Cu specific skin studies are limited, the shared mechanisms suggest similar benefits
In addition, the manufacturing facility is also inspected as part of the review process
Both medications belong to a class called incretin mimetics, but tirzepatide engages a second hormone pathway that semaglutide does not